VolitionRX (VNRX) to Release Quarterly Earnings on Thursday

VolitionRX (NYSEAMERICAN:VNRX) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $0.7160 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Friday, November 14, 2025 at 8:30 AM ET.

VolitionRX Stock Performance

VolitionRX stock opened at $0.43 on Thursday. The firm has a market cap of $46.27 million, a price-to-earnings ratio of -1.72 and a beta of 1.27. VolitionRX has a 1 year low of $0.40 and a 1 year high of $0.94. The firm’s 50 day moving average price is $0.56 and its two-hundred day moving average price is $0.60.

About VolitionRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.